Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate.

Author: ChiodiniAnnalisa, CrosignaniPier Giorgio, De GiorgiOlga, PasinRoberta, PietropaoloGiuliana, VercelliniPaolo

Paper Details 
Original Abstract of the Article :
OBJECTIVE: To evaluate the efficacy, safety, and tolerability of an estrogen-progestogen combination versus low-dose norethindrone acetate in the treatment of persistent pain after surgery for symptomatic rectovaginal endometriosis. DESIGN: Randomized controlled trial. SETTING: Academic center. P...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1016/j.fertnstert.2005.03.083

データ提供:米国国立医学図書館(NLM)

Managing Symptomatic Rectovaginal Endometriosis: Comparing Treatment Options

Rectovaginal endometriosis, a condition where uterine tissue grows outside the uterus, can cause debilitating pain and discomfort. This study compares the efficacy and tolerability of two medical treatments for persistent pain after surgery for rectovaginal endometriosis: an estrogen-progestogen combination and low-dose norethindrone acetate. The authors enrolled 90 women with recurrent pelvic pain after unsuccessful surgery, randomly assigning them to receive either treatment for 12 months. Their findings indicate that both treatments effectively reduced pain symptoms, with similar efficacy and tolerability. The study highlights the potential of low-dose norethindrone acetate as a cost-effective and well-tolerated alternative to repeat surgery for managing symptomatic rectovaginal endometriosis in women who are not seeking conception.

Norethindrone Acetate: A Viable Option for Endometriosis Pain

The study reveals that low-dose norethindrone acetate, a progestin medication, provides an effective and well-tolerated alternative to repeat surgery for managing persistent pain after surgery for rectovaginal endometriosis. This research offers valuable insight for clinicians seeking to optimize treatment strategies for women with this challenging condition, particularly those who are not seeking conception.

Understanding Endometriosis: Managing Pain and Discomfort

Endometriosis, a condition affecting millions of women, can cause significant pain and discomfort. This study highlights the potential benefits of medical treatments, like low-dose norethindrone acetate, in managing persistent pain after surgery. It's important to consult with your doctor to discuss appropriate treatment options for managing endometriosis, ensuring effective pain relief and improving quality of life.

Dr. Camel's Conclusion

Like a camel navigating a desert filled with treacherous sand dunes, women with rectovaginal endometriosis often face a challenging journey of persistent pain and discomfort. This study, like a compass guiding us through this intricate landscape, sheds light on effective treatment options, offering hope for finding relief from this debilitating condition. It's a reminder that with proper care and personalized approaches, we can navigate the challenges of endometriosis and strive for a better quality of life.

Date :
  1. Date Completed 2006-01-18
  2. Date Revised 2018-12-01
Further Info :

Pubmed ID

16275232

DOI: Digital Object Identifier

10.1016/j.fertnstert.2005.03.083

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.